|
|
Article: Takeda Pharmaceuticals North America Shares Early Stage Data on Sleep Compound, TAK-375; Data Presented at the American Psychiatric Association Meeting Reveals Mechanism of Action and Unique Binding Site.
- Article from:
- PR Newswire
- Article date:
- May 21, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO -- SAN FRANCISCO, May 21 /PRNewswire/ -- Results from early-stage trials demonstrate that TAK-375, under development by Takeda Pharmaceuticals North America (TPNA) for chronic and transient insomnia, is a highly selective ML-1 receptor agonist. The ML-1 receptor is a key mediator of natural sleep and may be an important new target for sleep agents.
In pre-clinical studies presented today at the American Psychiatric Association (APA) annual meeting in San Francisco, TAK-375 showed high selectivity for the ML-1 receptor with greater affinity, selectivity, and potency than melatonin, which is produced by the pineal gland and known to regulate sleep ...
Related newspaper, magazine, and journal articles:
|
|
Article: Takeda Pharmaceuticals North America Selects ...
Business Wire;
October 21, 2002 ;
700+ words
... ... today announced that Takeda Pharmaceuticals North America, Inc., a ... President of Sales at Takeda Pharmaceuticals North America. "There is ... 415/277-8200. Takeda Pharmaceuticals North America, Inc. Based ...
|
|